...
首页> 外文期刊>Drugs of the Future >Oxazolidinone Antibacterial
【24h】

Oxazolidinone Antibacterial

机译:恶唑烷酮抗菌

获取原文
获取原文并翻译 | 示例
           

摘要

RBx-7644 (ranbezoiid hydrochloride) is an extended-spectrum oxazolidinone that not only retains the excellent activity of linezofid against important Gram-positive pathogens, but also displays exquisite activity against all anaerobes (Gram-positive or Gram-negative) tested and has significant inhibitory activity against slime-producing and glass-adherent bacteria. Like linezolid, RBx-7644 has a novel mode of action, binding to the 50S ribosomal subunit and preventing it from forming a complex with the 30S subunit and initiation factors, resulting in blockade of the initiation of protein biosynthesis in prokaryotes. Due to its novel mode of action, RBx-7644 is active against pathogens that have acquired resistance to existing drugs. RBx-7644 was highly active by both the oral and parenter-al routes in mouse models of infection and displayed good oral bioavailability in mice, rats and dogs. In phase I studies, oral RBx-7644 was rapidly absorbed, safe and well tolerated. Its profile suggests potentially expanded indications for use and a reduced liklihood for resistance development.
机译:RBX-7644(Ranbezoiid盐酸盐)是一种扩展的恶唑胺蛋白,不仅保留了针对重要的革兰氏阳性病原体的Linezofid的优异活性,而且还显示出对所有厌氧(革兰氏菌或革兰氏阴性)进行的精致活性并具有显着性对粘液和玻璃粘附细菌的抑制活性。与Linezolid一样,RBX-7644具有新的作用方式,与50s核糖体亚基结合并防止其与30S亚基和起始因子形成复合物,导致蛋白质生物合成在原核生物中的启动。由于其新的动作模式,RBX-7644对针对获得对现有药物抗性的病原体是活性的。 RBX-7644通过口腔感染模型中的口腔和父母群途径高度活跃,并在小鼠,大鼠和狗中显示出良好的口服生物利用度。在I阶段研究中,口服RBX-7644迅速吸收,安全且耐受良好。其简介表明潜在扩大的使用迹象和抵抗力发展的减少的概念。

著录项

  • 来源
    《Drugs of the Future》 |2003年第11期|共8页
  • 作者

    Ashok Rattan;

  • 作者单位

    Ranbaxy Research Laboratories Microbiology New Drug Discovery Research Plot 20 Sector 18 122002 Gurgaon Haryana India.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号